ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

ClinicalTrials.gov ID: NCT03719690

Public ClinicalTrials.gov record NCT03719690. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 12:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Study identification

NCT ID
NCT03719690
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Kura Oncology, Inc.
Industry
Enrollment
296 participants

Conditions and interventions

Interventions

  • HRAS Detection Assay Device
  • Tipifarnib Drug

Device · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 14, 2019
Primary completion
May 1, 2023
Completion
May 1, 2023
Last update posted
Jun 20, 2024

2019 – 2023

United States locations

U.S. sites
29
U.S. states
20
U.S. cities
26
Facility City State ZIP Site status
University of Southern California Norris Comprehensive Cancer Center Los Angeles California 90033
UCLA - Jonsson Comprehensive Cancer Center Los Angeles California 90095
UCSF - Helen Diller Family Comprehensive Cancer Center San Francisco California 94158
The Oncology Institute of Hope and Innovation - Anaheim Whittier California 90603
Miami Cancer Institute Miami Florida 33176
University of South Florida H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612
Winship Cancer Institute Atlanta Georgia 30322
University of Chicago Chicago Illinois 60637
University Of Kansas Medical Center Westwood Kansas 66205
University of Kentucky Markey Cancer Center Lexington Kentucky 40536
Norton Cancer Institute Louisville Kentucky 40202
Greater Baltimore Medical Center Baltimore Maryland 21204
Marlene and Stewart Greenebaum Cancer Center Baltimore Maryland 21287
Dana Farber Cancer Institute Boston Massachusetts 02115
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201
Mayo Clinic Rochester Minnesota 55905
Siteman Cancer Center - Washington University Medical Campus St Louis Missouri 63129
New York University Langone Medical Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10065
Levine Cancer Institute Charlotte North Carolina 28204
The Ohio State University Columbus Ohio 43210
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Vanderbilt University Medical Center-Vanderbilt Ingram Cancer Center Nashville Tennessee 37232
San Antonio Military Medical Center Fort Sam Houston Texas 78234
The University of Texas MD Anderson Cancer Center Houston Texas 77030
University of Texas Health San Antonio - Mays Cancer Center San Antonio Texas 78229
Seattle Cancer Care Alliance Seattle Washington 98109
University of Wisconsin Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03719690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 20, 2024 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03719690 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →